ProCE Banner Activity

HER3 as a Target for ADCs: Rationale and Clinical Evidence

Slideset

Download this slideset from a live symposium at AACR 2023 to review expert perspectives on structural features and current clinical data with HER3-targeted antibody-drug conjugates, with a focus on use of these agents in breast and lung cancers.

Released: April 19, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.